Should the patient with a solitary kidney and rheumatoid arthritis continue oral Augmentin (amoxicillin/clavulanate) and his current maintenance dose of prednisone for the infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Should the patient continue Augmentin and prednisone?

Yes, the patient should continue both Augmentin and his current maintenance dose of prednisone for the infection. The presence of an active infection does not require stopping maintenance glucocorticoids in rheumatoid arthritis patients, and Augmentin is appropriate for use in patients with renal impairment.

Prednisone Management During Infection

Continue the current maintenance dose of prednisone without interruption. The ACR guidance explicitly states that glucocorticoids should be continued at the lowest effective dose to control underlying disease and avoid adrenal insufficiency, even in the context of infection 1, 2. The FDA label reinforces that abrupt withdrawal should be avoided, and patients on long-term therapy remain vulnerable during stressful situations like infections 3.

Key Considerations for Glucocorticoid Continuation:

  • Adrenal suppression risk: Patients on chronic prednisone have suppressed HPA axis function and cannot mount an adequate stress response if steroids are stopped 3
  • Disease control: Stopping prednisone risks an RA flare, which could compound the patient's clinical situation 4
  • Infection management: While high-dose glucocorticoids (>20 mg/day prednisone equivalent) increase infection risk 4, maintenance doses should be continued to prevent adrenal crisis 1, 2

Important caveat: If the patient requires stress-dose steroids due to severe infection, this should be considered separately from the maintenance dose. However, the 2017 ACR/AAHKS guideline recommends continuing the current daily dose rather than administering supraphysiologic "stress dosing" in most situations 4.

Augmentin Use in Solitary Kidney

Augmentin can be safely continued with appropriate dose adjustment for renal function. Research specifically demonstrates that amoxicillin-clavulanate provides effective prophylaxis against wound infections in renal failure patients, with bactericidal concentrations maintained for up to 20 hours post-operatively in dialysis patients 5.

Dosing Considerations:

  • Renal adjustment required: Antibiotic dosing must be carefully evaluated based on the patient's current renal function 6
  • Monitoring: The patient's nephrologist should be consulted regarding appropriate dose adjustments given the solitary kidney status
  • Efficacy: Augmentin remains effective in renal impairment when properly dosed 5

Common Pitfalls to Avoid:

  1. Do not abruptly stop prednisone - This can precipitate adrenal crisis, particularly dangerous during the stress of infection 3
  2. Do not use standard Augmentin dosing - Dose must be adjusted for renal function to prevent drug accumulation 6
  3. Do not assume immunosuppression requires stopping all medications - The evidence shows maintenance glucocorticoids should continue during infection 1, 2

Monitoring Strategy

While continuing both medications:

  • Monitor infection response: Assess clinical improvement on Augmentin therapy
  • Watch for adverse effects: Gastrointestinal symptoms are more common with amoxicillin-clavulanate (RR 1.15) 7
  • Renal function surveillance: Given solitary kidney, monitor creatinine and adjust Augmentin dosing accordingly 6
  • Glucocorticoid effects: Maintain vigilance for signs of inadequate infection control, which could indicate need for infectious disease consultation rather than medication changes

The combination of maintaining prednisone for RA control while treating infection with appropriately-dosed Augmentin represents the evidence-based approach for this clinical scenario.

Related Questions

In a rheumatoid arthritis patient with a solitary kidney who is currently on maintenance prednisone and being treated for an infection with amoxicillin‑clavulanate, should the prednisone dose be increased to 30 mg or 40 mg daily?
What is the appropriate augmentin (amoxicillin‑clavulanate) dose for an 87‑year‑old patient with chronic kidney disease stage IV being treated for bacterial sinusitis?
What is the appropriate adult dose of amoxicillin‑clavulanate for an 86‑year‑old patient with intact renal function who has a wound infection?
In a patient with established rheumatoid arthritis who develops an acute infection, what is the role of steroids and how should they be managed?
A 35-year-old woman with sinus congestion and sore throat who completed a 7‑day course of Augmentin (amoxicillin‑clavulanate) reports worsening symptoms; what are the next steps in management?
What is the appropriate workup for a patient with erythema of the foot?
In a patient using menthol‑methyl salicylate cream, acetaminophen 325 mg oral tablets, and a diclofenac 1.25 % topical patch who reports inadequate pain control and has a history of gastro‑esophageal reflux disease, how should her pain be managed?
In a patient with diabetes using a Dexcom continuous glucose monitor, a solitary kidney, and rheumatoid arthritis, what steroid and antibiotic regimen should be used for infection while minimizing hyperglycemia and renal toxicity?
In a 24-year-old patient with an electrocardiogram showing slight ST‑segment elevation in leads aVL and V2, how should this finding be evaluated and managed?
In a 54-year-old female with a right cheek abscess and a history of hidradenitis suppurativa (first facial lesion), what additional therapy besides doxycycline, such as ceftriaxone, should be considered to reduce swelling and pain?
What are the indications for using biologic therapies such as dupilumab, mepolizumab, benralizumab, or omalizumab in a patient with chronic sinus congestion, recurrent sinus infections, allergic sinusitis, and a persistently elevated peripheral eosinophil count of 280 cells/µL (greater than 150 cells/µL)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.